Agios Pharmaceuticals, Inc. (AGIO): Capital Expenditures
$4.32M
Year ended 2025-12-31
$4.66M
Trailing 12 months to 2026-06-30
-4.0%
3-year compound annual growth
-21.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.32M | +156.1% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $1.69M | +68.7% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $999.0K | -79.5% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $4.88M | -15.0% | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $5.74M | -59.3% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $14.11M | +17.3% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $12.03M | n/c | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $6.99M | +51.0% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $4.63M | -53.3% | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | $9.91M | -50.8% | 2019-02-14, From 2016-01-01 |
| 2015-12-31 | $20.16M | +809.9% | 2018-02-14, From 2015-01-01 |
| 2014-12-31 | $2.22M | +71.3% | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | $1.29M | -12.3% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $1.48M | -22.6% | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | $1.91M | n/a | 2014-03-18, From 2011-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $4.32M | +156.1% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $0 | -100.0% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $191.0K | -65.5% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $171.0K | -88.4% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $12.01M | +832.5% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $29.0K | -87.3% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Journey Medical Corp (DERM) | 2024-12-31 | $15.00M | +200.0% |
Compare AGIO, QTTB, INBP, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗